Literature DB >> 34358943

COVID-19 vaccines and multiple sclerosis disease-modifying therapies.

Gavin Giovannoni1, Christopher H Hawkes2, Jeannette Lechner-Scott2, Michael Levy2, E Ann Yeh2, David Baker2.   

Abstract

Entities:  

Year:  2021        PMID： 34358943     DOI： 10.1016/j.msard.2021.103155

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN： 2211-0348            Impact factor:   4.339


× No keyword cloud information.
  7 in total

1.  Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?

Authors:  David Baker; Amy MacDougall; Angray S Kang; Klaus Schmierer; Gavin Giovannoni; Ruth Dobson
Journal:  Clin Exp Immunol       Date:  2022-05-12       Impact factor: 4.330

2.  Seroconversion following COVID-19 vaccination: Can we optimize protective response in CD20-treated individuals?

Authors:  David Baker; Amy MacDougall; Angray S Kang; Klaus Schmierer; Gavin Giovannoni; Ruth Dobson
Journal:  Clin Exp Immunol       Date:  2021-11-18       Impact factor: 5.732

Review 3.  Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination.

Authors:  Maryam Golshani; Jiří Hrdý
Journal:  Vaccines (Basel)       Date:  2022-02-11

4.  How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?

Authors:  Gavin Giovannoni
Journal:  Mult Scler Relat Disord       Date:  2022-04-11       Impact factor: 4.808

5.  Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod.

Authors:  Magdalena Krbot Skorić; Dunja Rogić; Ivana Lapić; Dragana Šegulja; Mario Habek
Journal:  Mult Scler Relat Disord       Date:  2021-11-29       Impact factor: 4.339

6.  B Cell Depletion and SARS-CoV-2 Vaccine Responses in Neuroimmunologic Patients.

Authors:  Stefan Winkler; Judith H Aberle; Selma Tobudic; Barbara Kornek; Fritz Leutmezer; Paulus S Rommer; Maximilian Koblischke; Lisa Schneider; Helmuth Haslacher; Renate Thalhammer; Fritz Zimprich; Gudrun Zulehner; Gabriel Bsteh; Assunta Dal-Bianco; Walter Rinner; Karin Zebenholzer; Isabella Wimmer; Anja Steinmaurer; Marianne Graninger; Margareta Mayer; Kilian Roedl; Thomas Berger
Journal:  Ann Neurol       Date:  2022-02-08       Impact factor: 11.274

7.  Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study.

Authors:  Gabriel Bsteh; Harald Hegen; Gerhard Traxler; Nik Krajnc; Fritz Leutmezer; Franziska Di Pauli; Barbara Kornek; Paulus Rommer; Gudrun Zulehner; Sophie Dürauer; Angelika Bauer; Sarah Kratzwald; Sigrid Klotz; Michael Winklehner; Florian Deisenhammer; Michael Guger; Romana Höftberger; Thomas Berger
Journal:  Eur J Neurol       Date:  2022-02-09       Impact factor: 6.288
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.